Aion Medicines Presents Data at ObesityWeek Demonstrating Ultra-long-acting Pharmacokinetics and Pharmacodynamic Effects of AM-710, a Potential Best-in-clas…

Aion Medicines, a subsidiary of Exavir Therapeutics, announced the presentation of preclinical data for AM-710, the company’s ...
TipRanks on MSN

AstraZeneca’s AZD6234 Study: Key Insights for Investors

AstraZeneca (($AZN)) announced an update on their ongoing clinical study. AstraZeneca’s recent study titled ‘A Phase I, Multicentre, Single-Dose, ...
Medscape

Pharmacokinetics and Pharmacodynamics of Intranasal Versus Intravenous Fentanyl in Patients with Pain after Oral Surgery

Background: Fentanyl, a short-acting synthetic opioid, has a pharmacokinetic profile suited to fast relief of brief episodic pain. Objective: To characterize the pharmacokinetic-pharmacodynamic ...

Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025

The Company’s investigational small molecule glucagon-like peptide-1 (“GLP-1”) receptor agonist (“RA”), BMF-650, demonstrated potent weight loss and good tolerability in obese cynomolgus monkeys A ...
TipRanks on MSN

Bayer’s New Study on Sevabertinib: Implications for Cancer Treatment and Market Impact

Bayer AG (($BAYRY)) announced an update on their ongoing clinical study. Study Overview: Bayer AG is conducting a Phase 1 study titled A Phase 1, ...